Tag Archives: Molecular Pathology v. Myriad Genetics

Myriad Decision: Praise and Perils for Biotechnology Patent Policy

The Supreme Court decision blocking patents on naturally-occurring genes has generated predictions of doom for biotech innovation, along with expectations of more healthy competition in discovering new treatments and diagnostics. Although some commentators regarded the decision, Association for Molecular Pathology v. Myriad Genetics, as a “major reversal” in longstanding patent policy, many leaders of the […]
Posted in Biotech, Gene therapy, IP, Legal, Technology | Also tagged , , , | 2 Comments
  • Categories

  • Meta